WO2014151230A3 - Method of treating granulomatosis with polyangiitis - Google Patents

Method of treating granulomatosis with polyangiitis Download PDF

Info

Publication number
WO2014151230A3
WO2014151230A3 PCT/US2014/025247 US2014025247W WO2014151230A3 WO 2014151230 A3 WO2014151230 A3 WO 2014151230A3 US 2014025247 W US2014025247 W US 2014025247W WO 2014151230 A3 WO2014151230 A3 WO 2014151230A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyangiitis
granulomatosis
treating
methods
relates
Prior art date
Application number
PCT/US2014/025247
Other languages
French (fr)
Other versions
WO2014151230A2 (en
Inventor
Carol LANGFORD
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of WO2014151230A2 publication Critical patent/WO2014151230A2/en
Publication of WO2014151230A3 publication Critical patent/WO2014151230A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for treating granulomatosis with polyangiitis. More specifically the invention relates to methods of treating non-severe relapsing granulomatosis with polyangiitis by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
PCT/US2014/025247 2013-03-15 2014-03-13 Method of treating granulomatosis with polyangiitis WO2014151230A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361787160P 2013-03-15 2013-03-15
US61/787,160 2013-03-15
US201461950930P 2014-03-11 2014-03-11
US61/950,930 2014-03-11

Publications (2)

Publication Number Publication Date
WO2014151230A2 WO2014151230A2 (en) 2014-09-25
WO2014151230A3 true WO2014151230A3 (en) 2014-11-13

Family

ID=50639935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/025247 WO2014151230A2 (en) 2013-03-15 2014-03-13 Method of treating granulomatosis with polyangiitis

Country Status (1)

Country Link
WO (1) WO2014151230A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137424A1 (en) * 2008-05-05 2009-11-12 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
ES2667203T3 (en) 2000-07-03 2018-05-10 Bristol-Myers Squibb Company Uses of soluble CTL4 mutant molecules
JP4541157B2 (en) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー Mammalian cell culture methods for producing proteins
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137424A1 (en) * 2008-05-05 2009-11-12 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. LANGFORD ET AL: "An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener's) (GPA)", LA PRESSE MÉDICALE, vol. 42, no. 4, 1 April 2013 (2013-04-01), pages 770, XP055139376, ISSN: 0755-4982, DOI: 10.1016/j.lpm.2013.02.280 *
CHRISTIAN PAGNOUX ET AL: "Granulomatose de Wegener", LA PRESSE MÉDICALE, vol. 36, no. 5, 1 May 2007 (2007-05-01), pages 860 - 874, XP055139389, ISSN: 0755-4982, DOI: 10.1016/j.lpm.2007.02.015 *
LARRY MORELAND ET AL: "Abatacept", NATURE REVIEWS DRUG DISCOVERY, vol. 5, no. 3, 1 March 2006 (2006-03-01), pages 185 - 186, XP055139391, ISSN: 1474-1776, DOI: 10.1038/nrd1989 *
MANNA R ET AL: "Wegener's granulomatosis: an update on diagnosis and therapy.", EXPERT REVIEW OF CLINICAL IMMUNOLOGY JUL 2008, vol. 4, no. 4, July 2008 (2008-07-01), pages 481 - 495, XP009180064, ISSN: 1744-8409 *

Also Published As

Publication number Publication date
WO2014151230A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2021002406A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor.
MX2021015234A (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan.
MX347164B (en) Anti il-36r antibodies.
MD20140035A2 (en) Method for treating hepatitis C virus
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2016004551A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis.
PH12014502406B1 (en) Anti-il-23p19 antibodies
UA118666C2 (en) Novel pyrazol derivatives
MX2014004074A (en) Methods of treating liver conditions using notch2 antagonists.
PH12014502628A1 (en) Compositions and methods related to the prevention and treatment of rabies infection
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MX2016005760A (en) Gsk-3 inhibitors.
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
NZ722600A (en) Methods of treating mild brain injury
EP3027049A4 (en) Treatment of beverages to reduce the effects of noxious constituents
EA201591434A1 (en) METHOD OF PROVIDING THE EYE NEUROPROTECTION
EA201491581A1 (en) ВЕЗИКУЛЯРНЫЕ КОМПОЗИЦИИ
MX2015016603A (en) Corticosteroid compositions.
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14721605

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14721605

Country of ref document: EP

Kind code of ref document: A2